20/20 Biolabs Inc. Common Stock (AIDX)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business that earns money and has a durable advantage. 20/20 Biolabs does not yet show either. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $730,571 and a net loss of $1.5 million, or diluted EPS of $-0.26. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $353,375 and net loss was $2.2 million, or $-0.28. For FY2025, the year ended 2025-12-31, revenue was $2.0 million, net loss was $3.7 million, and diluted EPS was $-0.76; FY2024, the year ended 2024-12-31, had revenue of $1.8 million, net loss of $5.6 million, and diluted EPS of $-1.16. So losses narrowed and revenue edged up, but the company remains deeply unprofitable and generated trailing free cash flow of -$2.8 million. At the 2026-10-13 close of $0.35, the market cap was only $4.5 million. FairStock calculations show P/B of 2.69 and a negative P/E of -0.60; trailing FCF yield is -62.7%. ROE is -331.22%, ROCE is -62.37%, and Altman Z-Score is -7.90, all pointing to financial distress. Debt/equity of 0.18 is modest, and Piotroski F-Score of 6/9 is not terrible, but the FairStock Score is 17/100. The business has just four employees, revenue under $1 million in the latest quarter, and only two years of filed results; FairStock assigns no Lynch category because it needs three years. I see no margin of safety. A $4.5 million price for a cash-burning micro-cap with no demonstrated moat is speculative, not value investing.

In plain English: 20/20 Biolabs is a tiny healthcare company selling lab blood tests that use AI to look for cancer and other diseases early. It brings in less than $1 million a quarter, loses money, and has a very short financial history, so the business looks weak today. At $0.35 a share, the price is not supported by profits or cash flow and looks expensive relative to the tiny, loss-making business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer